Nanobiotix reports strong financial results for Q1 2024, includes $20 million milestone payment.

From GlobeNewswire: 2024-05-22 02:00:00

Nanobiotix, a biotechnology company, reported financial results for the first quarter of 2024, including cash and cash equivalents of €58.9 million as of March 31, 2024. This amount is expected to fund operations into Q3 2025, inclusive of a $20 million milestone received. The company will host a conference call and webcast on May 22, 2024, providing updates and taking questions.
Nanobiotix, founded in 2003 and headquartered in Paris, is listed on Euronext Paris and the Nasdaq Global Select Market. The company owns over 25 patent families related to nanotechnology platforms used in oncology, bioavailability, and central nervous system disorders. Nanobiotix is committed to revolutionizing treatment outcomes for patients with disruptive, physics-based therapeutic approaches.
Participants can join the conference call and webcast to hear Nanobiotix’s CEO, Laurent Levy, discuss business activities. The company’s philosophy is focused on pushing boundaries to expand possibilities for human life. Forward-looking statements regarding the company’s financial resources and operations are included in the press release, with risks and uncertainties detailed in filings with the Securities and Exchange Commission.
For more information about Nanobiotix, visit their website or follow them on social media. Contacts for communication, investor relations, and media relations are provided for inquiries. Nanobiotix aims to make a difference for humanity through their innovative approaches to cancer treatment and other therapeutic areas.



Read more at GlobeNewswire:: NANOBIOTIX Provides First Quarter 2024 Operational and